<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2018-1-80-85</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-2273</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕВМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RHEUMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Нестероидные противовоспалительные препараты в терапии остеоартроза: сравнительная эффективность и переносимость препаратов нимесулида</article-title><trans-title-group xml:lang="en"><trans-title>NONSTEROID ANTI-INFLAMMATORY DRUGS FOR THE TREATEMENT OF OSTEOARTHROSIS: COMPARATIVE EFFICACY AND TOLERABILITY OF NIMESULIDE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бадокин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Badokin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, Prof</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российская медицинская академия непрерывного профессионального образования Минздрава России, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuing Postgraduate Education of the Ministry of Health of Russia, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>05</day><month>02</month><year>2018</year></pub-date><volume>0</volume><issue>1</issue><fpage>80</fpage><lpage>85</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бадокин В.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Бадокин В.В.</copyright-holder><copyright-holder xml:lang="en">Badokin V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/2273">https://www.med-sovet.pro/jour/article/view/2273</self-uri><abstract><p>Нестероидные противовоспалительные препараты относятся к основным средствам быстрого действия при остеоартрозе. Особенностью фармакологической активности многих из них является хондронегативное действие большинства из них на остеоартрозный хрящ, которое проявляется в угнетении метаболической активности хондроцитов и интенсификации их апоптоза, что способствует снижению синтеза протеогликанов – основного межклеточного вещества гиалинового хряща и, соответственно, нарастанию темпов его дегенерации. Нимесулиды, напротив, обладают хондронегативным действием. В работе представлены результаты сравнительного рандомизированного исследования по оценке эффективности и переносимости двух дженериков нимесулида – препаратов Нимесан и Найз. Нимесан по своим характеристикам не только не уступал препарату Найз, но и оказался более эффективным по суммарному индексу WOMAC, положительной динамике функциональной способности пораженных суставов и показателю СОЭ. По своей переносимости и безопасности оба препарата показали сравнимые результаты.</p><p> </p></abstract><trans-abstract xml:lang="en"><p>Nonsteroid anti-inflammatory drugs are the fast-acting medications used widely to treat pain and inflammation for osteoarthritis. The pharmacological activity of most of them is characterized by the chondronegative action on osteoarthrosis cartilage, which manifests itself as inhibition of the chondrocyte metabolic activity and intensification of its apoptosis, which reduces the synthesis of proteoglycans, the main intercellular substance of the hyaline cartilage and thus its degeneration rates. In contrast, nimesulides show a chondronegative action. The article presents the results of a comparative randomized study evaluating the efficacy and tolerability of two Nimesulide generics, Nimesan and Nise. Nimesan was not only inferior to Nise by its characteristics, but also proved to be more efficient by the overall WOMAC index, positive dynamics of the functional capacity of the affected joints and the ESR index. Both drugs showed comparable tolerability and safety results.</p><p> </p></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартроз</kwd><kwd>нимесулид</kwd><kwd>Нимесан</kwd><kwd>Найз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthrosis</kwd><kwd>nimesulide</kwd><kwd>Nimesan</kwd><kwd>Nise</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Reid JL, Morton DJ, Wingard DD et al. Obesity and other cardiovascular disease risk factors and their association with osteoarthritis in Southern California American Indians, 2002–2006. Ethn. Dis., 2010, 20(4): 416–22.</mixed-citation><mixed-citation xml:lang="en">Reid JL, Morton DJ, Wingard DD et al. Obesity and other cardiovascular disease risk factors and their association with osteoarthritis in Southern California American Indians, 2002–2006. Ethn. Dis., 2010, 20(4): 416–22.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Berg W.B. Pathophysiology of osteoarthritis. Joint Bone Spine, 2000, 67(6): 555–56.</mixed-citation><mixed-citation xml:lang="en">Van den Berg W.B. Pathophysiology of osteoarthritis. Joint Bone Spine, 2000, 67(6): 555–56.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Martel-Pelletier J, Pelletier J-P. Inflammatory factors involved in osteoarthritis. Osteoarthritis, Inflammation and Degradation: A Continuum. Eds. JA Buckwalter, M Lotz, J-F Stoltz. IOS Press. 2007.</mixed-citation><mixed-citation xml:lang="en">Martel-Pelletier J, Pelletier J-P. Inflammatory factors involved in osteoarthritis. Osteoarthritis, Inflammation and Degradation: A Continuum. Eds. JA Buckwalter, M Lotz, J-F Stoltz. IOS Press. 2007.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cart, 2008, 16(2): 137–162.</mixed-citation><mixed-citation xml:lang="en">Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cart, 2008, 16(2): 137–162.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е.Л. Перспективы применения нового нестероидного противовоспалительного препарата нимесулид. Клиническая фармакология и терапия, 1999, 1: 65–9.</mixed-citation><mixed-citation xml:lang="en">Насонов Е.Л. Перспективы применения нового нестероидного противовоспалительного препарата нимесулид. Клиническая фармакология и терапия, 1999, 1: 65–9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kullich WC, Niksic F, Klein G. Effect of nimesulide on metalloproteinas-es and matrix degradation in osteoarthritis: a pilot clinical study. Int. J. Clin. Pract., 2002, Suppl. 128: 24–29.</mixed-citation><mixed-citation xml:lang="en">Kullich WC, Niksic F, Klein G. Effect of nimesulide on metalloproteinas-es and matrix degradation in osteoarthritis: a pilot clinical study. Int. J. Clin. Pract., 2002, Suppl. 128: 24–29.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев А.Е. Нимесулид: вопросы безопасности и возможность длительного применения. Фарматека, 2009, 4: 17–25.</mixed-citation><mixed-citation xml:lang="en">Каратеев А.Е. Нимесулид: вопросы безопасности и возможность длительного применения. Фарматека, 2009, 4: 17–25.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kriegel W, Korff KJ, Ehrlich JC et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int. J. Clin. Pract., 2001, 55(8): 510–14.</mixed-citation><mixed-citation xml:lang="en">Kriegel W, Korff KJ, Ehrlich JC et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int. J. Clin. Pract., 2001, 55(8): 510–14.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf, 2001, 24(14): 1081–90.</mixed-citation><mixed-citation xml:lang="en">Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf, 2001, 24(14): 1081–90.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bruyère O, Cooper C, Pelletier JP et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin. Arthritis Rheum., 2014, 44(3): 253-63.</mixed-citation><mixed-citation xml:lang="en">Bruyère O, Cooper C, Pelletier JP et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin. Arthritis Rheum., 2014, 44(3): 253-63.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
